Genetic testing and diagnostics by Fulgent Genetics
Epic Aura integration to add Fulgent Genetics testing to provider workflows
Fulgent Genetics announced plans to join the Epic Aura network in the fourth quarter of 2026, enabling healthcare providers to order Fulgent testing and receive results within the existing Epic ...
Fulgent Genetics expands skeletal dysplasia panel by 188 genes and vascular panel by 29
Fulgent Genetics reported a significant expansion of its genetic testing panels, adding 188 genes to its skeletal dysplasia panel and 29 to its vascular malformation panel last month. The broader ...
Fulgent Genetics calls for provider-driven lab menu innovation
Fulgent Genetics now offers more than 18,000 single gene tests and over 900 panel tests through a single laboratory. This expansion aims to simplify the workflow for healthcare providers and ...
Fulgent Genetics expands genomics outreach through publications and presentations
Fulgent Genetics is reinforcing its commitment to genomics by contributing to the field across multiple platforms. The company’s team participates in peer-reviewed publications, delivers ...
Fulgent Genetics details new protocols for variant reclassification and segregation testing recommendations
Fulgent Genetics has introduced new guidance outlining how the company approaches genetic variant reclassification and when segregation testing is advisable. This update is designed to support ...
Fulgent Genetics focuses on partnership approach to patient care
Fulgent Genetics underscores the importance of building close partnerships with clinicians and patients in laboratory services. The company suggests that its value lies not just in delivering ...
Fulgent Genetics unveils FulGenome upgrade with higher repeat expansion detection
Fulgent Genetics has announced a major update to its FulGenome whole genome sequencing (WGS) solution. The latest version now detects 64 repeat expansions, a significant increase from the previous ...
Fulgent Genetics presents updated Phase 2 data on FID-007 plus cetuximab, plans Phase 3 trial
Fulgent Genetics presented updated Phase 2 clinical trial data for its FID-007 therapy in combination with cetuximab at the ASCO26 conference today. The company expressed gratitude to patients, ...
Fulgent Genetics reports promising 60 percent response in phase 2 FID-007 cetuximab trial
Fulgent Genetics released interim results from its phase 2 trial of FID-007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). ...
Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair
Fulgent Genetics announced its participation in the APG2026 Exhibit Fair and Strolling Dinner, scheduled for Thursday, May 28 from 6:00 to 9:00 PM in San Diego. The company aims to connect with ...
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males
Fulgent Genetics has significantly expanded its infertility next-generation sequencing (NGS) panels, adding 41 genes to the Female Infertility Panel—bringing the total to 143, including all ...
Fulgent Genetics to present nano-encapsulated anti-tumor drug FID-007 efficacy at ASCO meeting
Fulgent Genetics will present new findings on the efficacy of its nano-encapsulated anti-tumor drug FID-007 at this year's American Society of Clinical Oncology (ASCO) meeting. The drug, which ...
